Obexia "the weight switch company" is a biotech startup focused on the development of breakthrough therapies for cancer cachexia (wasting syndrome), a frequent condition with significant unmet need that is directly associated with dismal quality of life and early death. OBX1201, our lead product has the potential to become a first-in-class treatment for cancer cachexia. We will demonstrate clinical proof-of-concept & sell OBX1201 to big pharma.